Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
M Markman, P Francis, E Rowinsky, T Hakes, B Reichman, W Jones, JL Lewis, S Rubin, J Curtin, R Barakat
Annals of Oncology | Published : 1994
In an effort to examine the safety and pharmacology of the intraperitoneal (i.p.) delivery of paclitaxel, 25 patients (24 with ovarian cancer) were treated in a phase I dose escalation trial. The drug was administered in normal saline every 3 to 4 weeks, starting at a dose of 25 mg/m2. The dose-limiting toxicity at doses at or above 175 mg/m2 was abdominal pain. A 3-log pharmacokinetic advantage for peritoneal cavity exposure to paclitaxel, compared with the systemic compartment, was observed. High levels of drug persisted within the cavity for longer than 48 hours following a single treatment. In addition, significant paclitaxel concentrations were found in the systemic compartment after i...View full abstract